Logo: to the web site of Uppsala University

Antibiotics have been a pivotal pharmaceutical compound since their discovery in the early 20th century. Misuse of antibiotics in multiple sectors within our society has allowed antibiotic-resistant bacteria to arise and shortly commercial antibiotics could be rendered ineffective for treatment. Antimicrobial peptides (AMPs) are novel antimicrobial treatment options that could be used as a substitute for commercial antibiotics. Herein AMPs based on the KR-12 sequence, the active region of the human cathelicidin host defense peptide LL-37, have been investigated for the purpose to treat chronic wound bacterial infections. The two main AMPs for the current project are, one KR-12 monomer with an optimized sequence called KR12-Q5KD9A-CYS and one KR12 dimer utilizing a Glycine-proline linker named CD4-PP. Both monomer and dimerAMPs were conjugated onto nano-fibrillated cellulose (NFC) using thiol chemistry resulting in an ointment-like formulation which is referred to as PBF-10 and PBF-11 respectively. Antimicrobial activity, stability, and liposome leakage were assessed, and the result showed high antimicrobial activity, and liposome leakage capacity for both PBF-10 and PBF-11however PBF-11 seems to be more stable in serum. These results display the potential of utilizing CNF together with AMPs, preferably the dimeric CD4PP peptide, to address chronic wound infections and simultaneously alleviate selective pressure causing antibiotic resistance. Not only would an ointment-like formulation be suitable for local applications but the added stability whilst retaining the vital functions of the AMP is critical for proper healing of the wound. This current work could be used in the future as an intermediate to optimize the characteristics of both CNF and AMPs. For example, conjugation of the cyclic variant ofCD4PP, which already has shown to be more stable than its linear counterpart, could be synthesized to evaluate the synergistic effect of both cyclization and CNF conjugation.